药物支架植入后理想的抗血小板时间—更长或更短？

药物支架植入后理想的抗血小板时间—更长或更短？内容摘要：

中断 • 从未中断 • 首个 DAPT永久停用研究 SPIRITCOMPARE Meta DAPT Discontinuation, ACC 2020 Patients on Dual Antiplatelet Therapy At 1 Year At 2 Years XIENCE V % % Taxus % % 汇总数据库 n=6789 n=4247 XIENCE V n=4247 Taxus n=2542 2020 ACC Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。 2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 19 SPIRITCOMPARE荟萃分析 首个 DAPT永久停用研究 “随访观察使用 Xience治疗的患者至术后两年，发现在术后 1个月之后的任何时间永久性停用 DAPT对支架血栓的发生率没有造成影响。 ” PI Kedhi SPIRITCOMPARE Meta DAPT Discontinuation, ACC 2020 p = p = 2020 ACC Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。 2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 20 DAPT 中断研究 真实世界人群 • 汇总分析来自 4个真实世界研究的 10,615名患者数据 • 919 名患者在 312个月之间中断 DAPT使用 • “ DAPT 中断”包括暂时及永久停用 DAPT的患者 Source: Palmerini, T. PCR 2020. 研究 XIENCE V (n=10,615) 研究设计 患者人群 XIENCE V USA SPIRIT V SPIRIT WOMEN XIENCE V INDIA n=6,516 n=1,662 n=1,506 n=931 多中心，单臂 Open Label 真实世界 真实世界 真实世界 真实世界 2020 PCR Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。 2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 21 复杂的真实世界患者群 术后两年低支架血栓发生率 支架血栓 ARC 确定的/可能的 (%) % Pooled data of 10,615 patients from four realworld trials—XIENCE V USA (n=6516), SPIRIT V (n=1,662), SPIRIT WOMEN SAS (n=1,506) and XIENCE V India (n=931). Source: Palmerini, T., PCR 2020. 月 真实世界人群 (n=10,615) AMI 再狭窄 ACS 左主干 分叉病变 糖尿病 桥血管 开口病变 EF30% CTO 多支病变 直接支架 肾功能不全 多支血管治疗 2020 PCR Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。 2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 22 XIENCE 术 后 3个月后中断 DAPT 支架血栓 为 0% 首次中断 DAPT的 时间 及支架血栓 发 生率 随 访 至 12个月 Source: Palmerini T., PCR 2020. * Including patients with no DAPT Interruption except possibly after Stent Thrombosis though 365 days. 中断DAPT后出现的支架血栓 ARC 确定的/可能的 (%) % % % % 从未中断 * DAPT 中断 03 月 312 月 2020 PCR Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。 2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 23 内容 • 临 床使用 DAPT的 难题 • XIENCE DAPT中断 /停用数据 • 不同 DES的安全性表现 Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only, and not intended for physicians from France, Japan or the United States. 169。 2020 Abbott. All rights reserved. AP2936456OUS Rev. B. 24 XIENCE: 有证可循的表现 , 一项又一项的研究 研究超过 45,000 患者 1 随访时间长达 5 年 2 100余个 RCT研究 及注册研究 3 复杂病变患者的数据包括 : 左主干 AMI ACS 分叉病变 肾功能不全 多支病变 糖尿病 CTOs 桥血管 再狭窄病变 开口病变 All statements being made and data shown are reflective of the entire patient population in the study and are not representative of any specific lesion type. S Silber et al. Unrestricted randomized use of two new generation drugeluting coronary stents: 2year patientrelated versus stentrelated outes from the RESOLUTE All Comers trial. The Lancet. April 9, 2020。 377:124147。 M Krucoff. OneYear Results from the XIENCE V USA Condition of Approval Study, TCT 2020. 1. Based on patient numbers from various Abbott and nonAbbottsponsored trials. Data on file at Abbott Vascular. 2. Data from SPIRIT FIRST, SPIRIT II and SPIRIT III trials. 3. Trials registered on as of Aug. 3, 2020. Information contained herein is for Europe, Middle East and Africa, and Asia Pacific only,。